Health Canada Updates Guidance on Distribution of Canadian-Market Drugs Outside Canada
Health Canada has renumbered its compliance guidance, leaving drug distributors’ shortage-assessment and recordkeeping responsibilities intact.
Health Canada issued version 2 of GUI-0145 on October 7, 2026, replacing the November 28, 2021 edition of its guidance for distributing drugs intended for the Canadian market for consumption or use outside Canada. The department’s change log identifies the update as a renumbering of provisions, while the document remains an administrative tool intended to help regulated parties comply with applicable legislation and policies. [1]
The guidance concerns drug establishment licence holders, or DEL holders. It explains that a DEL holder cannot distribute a drug intended for the Canadian market for use outside Canada unless it has reasonable grounds to believe the distribution will not cause or worsen a Canadian shortage. Health Canada describes distribution in this context as including shipping, selling or delivering a drug, and says the prohibition applies to all DEL holders, including those that are not market authorization holders. [1]
The document sets out an assessment approach for licensees considering such distribution. Its first stage identifies circumstances that would bar the transaction, including where a drug is listed as a Tier 3 shortage, where distribution would impair the holder’s ability to fill Canadian customer orders in full and on time, or where all Canadian market authorization holders for comparable forms or strengths are reporting a shortage. Licensees are directed to consider available public information, their own business intelligence and information from affected supply-chain participants. [1]
The guidance also addresses documentation. It says DEL holders should maintain records demonstrating that their assessment was conducted appropriately, and indicates that further factors may need to be considered depending on the circumstances. For entities that are not market authorization holders, Health Canada says they should work with the relevant authorization holder where necessary to obtain information supporting the assessment. [1]
The scope covers several categories of drugs, including controlled substances, prescription drugs, radiopharmaceuticals, biologics and specified products on the expanded scope list. The guidance excludes certain retail pharmacy sales, drugs imported solely for export, and drugs manufactured in Canada specifically for export. Health Canada stresses that guidance does not itself constitute legislation and that legislation prevails if there is a conflict. [1]
This is a limited implementation update rather than a new tariff, restriction or change to the underlying drug-shortage framework. The immediate exposure is concentrated among drug establishment licence holders that assess and document proposed distribution of Canadian-market drugs outside Canada; the published change is a renumbering of guidance provisions, so it does not by itself establish a broader cross-border trade disruption. [1]